TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31846504

Group type: EXPERIMENTAL
Intervention: Patients with reduced capacity to work (RCW)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Mean percentage reduced capacity to work (PRCW)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Total insurance costs for patients with RCW
Number of subjects: 1183
Study: 31847007

Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31847794

Group type: EXPERIMENTAL
Intervention: History of stroke or transient ischemic attack
Number of subjects: 5617

Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 5617

Group type: EXPERIMENTAL
Intervention: History of transient ischemic attack
Number of subjects: 5617
Study: 31847861

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment during adjuvant chemotherapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 310
Study: 31847910

Group type: EXPERIMENTAL
Intervention: Balancing Everyday Life (BEL) intervention
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: BEL intervention
Number of subjects: 133
Study: 31848165

Group type: EXPERIMENTAL
Intervention: Normal adiposity group receiving DFU management according to locally appropriate standards of care
Number of subjects: 300

Group type: COMPARATOR
Intervention: High adiposity group receiving DFU management according to locally appropriate standards of care
Number of subjects: 300
Study: 31848672

Group type: EXPERIMENTAL
Intervention: Same-day hepatic flow redistribution and Yttrium-90 radioembolization (90Y-RE)
Number of subjects: 22
Study: 31848762

Group type: EXPERIMENTAL
Intervention: Submerged two-stage implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonsubmerged one-stage implants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soft tissue parameters (PI, PD, BOP, REC) for both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vertical keratinized tissue thickness (KTT)
Number of subjects: 20
Study: 31848820

Group type: EXPERIMENTAL
Intervention: Preoperative high protein β-hydroxy-β-methyl butyrate oral nutritional support (ONS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postoperative nutritional support targeting at least 1 g/kg/day protein and 20 kcal/kg/day caloric intake
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postoperative evaluation of PEM
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation between PEM at surgery and postoperative complications
Number of subjects: 35
Study: 31848983

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 195

Group type: COMPARATOR
Intervention: Basal-Bolus regimen
Number of subjects: 195
Study: 31849164

Group type: EXPERIMENTAL
Intervention: Higher heart rate in patients in sinus rhythm (SR)
Number of subjects: 13462

Group type: EXPERIMENTAL
Intervention: Heart rate per 10 bpm increase in patients in sinus rhythm (SR)
Number of subjects: 13462

Group type: COMPARATOR
Intervention: Heart rate in patients in atrial fibrillation (AF)
Number of subjects: 13462
Study: 31849202

Group type: EXPERIMENTAL
Intervention: Ra-223 (55 kBq/kg intravenously every 4 weeks) up to 6 cycles with endocrine therapy
Number of subjects: 36
Study: 31849514

Group type: EXPERIMENTAL
Intervention: 10Hz transcranial alternating current stimulation (tACS) for 40 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 31849532

Group type: EXPERIMENTAL
Intervention: Group 2 (CTCs elevated at baseline and cleared postbaseline)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group 1 (elevated CTCs at baseline and postbaseline)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group 3 (no CTCs detected at baseline)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 126
Study: 31849531

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX-4
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX-4 alone
Number of subjects: 0
Study: 31849542

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week plus MTX (ETN+MTX)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Conventional DMARD plus MTX (DMARD+MTX)
Number of subjects: 423
Study: 31849628

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) applied before the 6 min walk test (6MWT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) applied during the 6 min walk test (6MWT)
Number of subjects: 12
Study: 31849715

Group type: EXPERIMENTAL
Intervention: Stress echocardiography derived tissue Doppler E/e' ratio
Number of subjects: 34

Group type: COMPARATOR
Intervention: Resting echocardiographic parameters
Number of subjects: 34
Study: 31850192

Group type: EXPERIMENTAL
Intervention: Nivolumab (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31850360

Group type: EXPERIMENTAL
Intervention: 25 g milk protein concentrate, 25 g maltodextrin, 7.75 g canola oil (treatment group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isocaloric protein void drink (placebo group)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 17
Study: 31850847

Group type: EXPERIMENTAL
Intervention: Web-based module for electronic patient-reported outcomes (PROs) collection (APPEGE 2.0)
Number of subjects: 15
Study: 31850853

Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Resident-run oral health campaigns
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Sequence BA (Campaign followed by AMI)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Sequence AB (AMI followed by Campaign)
Number of subjects: 360
Study: 31851315

Group type: EXPERIMENTAL
Intervention: DSMQ
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: Two 24HRs (mean)
Number of subjects: 11451

Group type: COMPARATOR
Intervention: Single 24HR
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: DSMQ or at least one 24HR
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: 24HR day 1
Number of subjects: 11451

Group type: COMPARATOR
Intervention: 24HR only
Number of subjects: 11451

Group type: COMPARATOR
Intervention: Mean 24HR
Number of subjects: 11451
Study: 31851518

Group type: EXPERIMENTAL
Intervention: DNA-PKcs inhibitors with good PI3 kinase selectivity
Number of subjects: 0
Study: 31851677

Group type: EXPERIMENTAL
Intervention: Pulmonary functional parameters
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Renal functional parameters
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bilateral kidney arterial resistivity index (RI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Glycaemia regulation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Right kidney RI
Number of subjects: 96
Study: 31851732

Group type: EXPERIMENTAL
Intervention: Patient-derived tumour models
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patient-specific renal cancer tumouroids
Number of subjects: 10
Study: 31851740

Group type: EXPERIMENTAL
Intervention: Simultaneous colorectal and liver resection
Number of subjects: 0
Study: 31851762

Group type: EXPERIMENTAL
Intervention: Busulfan dosing based on fat free mass (FFM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional dosing based on total body mass
Number of subjects: 29
Study: 31852086

Group type: EXPERIMENTAL
Intervention: Transforaminal epidural blocks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Percutaneous epidural neuroplasty (PEN) without additional blocks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Runoff group (PEN with contrast runoff)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-runoff group (PEN without contrast runoff)
Number of subjects: 112
Study: 31852421

Group type: EXPERIMENTAL
Intervention: HF with reduced ejection fraction (EF <40%)
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: HF with preserved ejection fraction (EF ≥50%)
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: Southeast Asian patients
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: South Asian patients
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: Northeast Asian patients
Number of subjects: 6480
Study: 31852497

Group type: EXPERIMENTAL
Intervention: Thermoplastic mask for head immobilization during stereotactic radiotherapy
Number of subjects: 5
Study: 31852717

Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo)
Number of subjects: 29
Study: 31852810

Group type: EXPERIMENTAL
Intervention: TLC388 (Lipotecan) Hydrochloride, 40 mg/m², administered for a median of 2 treatment cycles (range, 0-6)
Number of subjects: 23
Study: 31852847

Group type: EXPERIMENTAL
Intervention: Intermittent prednisone administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic daily steroid use
Number of subjects: 0
Study: 31853198

Group type: EXPERIMENTAL
Intervention: CC-115 10 mg BID
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CC-115 (various doses 0.5-40 mg/day)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CC-115 (10 mg BID)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CC-115 (in bioavailability substudy)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CC-115 (in cohort expansion)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CC-115 (in chronic lymphocytic leukemia/small lymphocytic lymphoma)
Number of subjects: 118
Study: 31853265

Group type: EXPERIMENTAL
Intervention: Capmatinib 300 mg BID
Number of subjects: 38
Study: 31853886

Group type: EXPERIMENTAL
Intervention: Innovative Clinical Score (ICS) developed using data from 325 patients.
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Innovative Clinical Score (ICS) validated using data from 106 patients.
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Calibration plots for the ICS.
Number of subjects: 431
Study: 31853896

Group type: EXPERIMENTAL
Intervention: Two-dimensional cranial ultrasonography for estimating absolute brain volumes (EABVs)
Number of subjects: 21
Study: 31855161

Group type: EXPERIMENTAL
Intervention: Active lighting intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control lighting intervention
Number of subjects: 46
Study: 31855189

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Health education group (control)
Number of subjects: 28
Study: 31855231

Group type: EXPERIMENTAL
Intervention: mcfDNA-seq
Number of subjects: 47
Study: 31855577

Group type: COMPARATOR
Intervention: Dynamic fluorine-19-enhanced MRI (19F MRI)
Number of subjects: 44
Study: 31856021

Group type: EXPERIMENTAL
Intervention: Delayed transfer (n = 69)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Early transfer (n = 239)
Number of subjects: 308
Study: 31856052

Group type: EXPERIMENTAL
Intervention: Stratified analgesia group (n=187)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Conventional group (n=174)
Number of subjects: 361
Study: 31856056

Group type: EXPERIMENTAL
Intervention: Ultrasound protocol (TRIP) for severity assessment of acute cor pulmonale (ACP) including tricuspid regurgitation velocity (T), right ventricular size (R), inferior vena cava diameter fluctuation (I), and pulmonary regurgitation velocity (P).
Number of subjects: 0
Study: 31856739

Group type: EXPERIMENTAL
Intervention: New standard operating procedures (SOPs) for resuscitation room including early whole-body CT, damage control surgery, and goal-directed coagulation management.
Number of subjects: 512

Group type: COMPARATOR
Intervention: Historic cohort (PreSOP)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: New SOPs
Number of subjects: 512
Study: 31856786

Group type: EXPERIMENTAL
Intervention: King's Brief Interstitial Lung Disease questionnaire (K-BILD)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: K-BILD
Number of subjects: 150
Study: 31856860

Group type: EXPERIMENTAL
Intervention: Cardiogenic shock (CS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Septic shock (SS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Septic controls (SC)
Number of subjects: 37
Study: 31857311

Group type: EXPERIMENTAL
Intervention: Antibiotic prescription (yes/no)
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Female GP sex
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: GP age (≥60 years)
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Patient age (≥65 years)
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Number of signs/symptoms (≥4)
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Fever
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Productive cough
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Otalgia
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Tender cervical nodes
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Regular clients
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Antibiotic requests
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Non-productive cough
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Sore throat
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Rhinorrhoea
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Dyspnoea
Number of subjects: 4831
Study: 31857726

Group type: EXPERIMENTAL
Intervention: Vismodegib added to gemcitabine and nab-paclitaxel starting on the second cycle
Number of subjects: 71

Group type: COMPARATOR
Intervention: Gemcitabine and nab-paclitaxel (historical control)
Number of subjects: 71
Study: 31858293

Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Number of subjects: 8
Study: 31858327

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg every 12 hours for six doses in a 7-day lead-in cycle (cycle 0) followed by 60 mg every 12 hours for six doses in a 14-day cycle (cycle 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 32
Study: 31858403

Group type: EXPERIMENTAL
Intervention: Point shear wave elastography (pSWE)
Number of subjects: 251
Study: 31858837

Group type: EXPERIMENTAL
Intervention: Home-Based Exercise Prehabilitation
Number of subjects: 0
Study: 31858880

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31859468

Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos extract (PLE) 480 mg daily for 28 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos extract (PLE)
Number of subjects: 22
Study: 31859686

Group type: EXPERIMENTAL
Intervention: Cash transfer delivered over 18 months in addition to other HIV interventions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Other HIV interventions without cash transfer
Number of subjects: 30
Study: 31859688

Group type: EXPERIMENTAL
Intervention: Rent subsidies for 24 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rent subsidies for 24 months + adult mentoring
Number of subjects: 24
Study: 31859705

Group type: EXPERIMENTAL
Intervention: Morning symptoms
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Nighttime symptoms
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Daytime symptoms
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Severe symptoms
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 593
Study: 31860140

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) 1.8 mg/kg with MEC (mitoxantrone, etoposide, cytarabine)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with MEC
Number of subjects: 22
Study: 31860525

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT with CT-based segmentation methodology
Number of subjects: 71
Study: 31861009

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Omadacycline (oral form)
Number of subjects: 368
Study: 31862084

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional short-term monitoring (STM) strategies
Number of subjects: 0
Study: 31862160

Group type: EXPERIMENTAL
Intervention: Postoperative cerebral oxygen saturation monitoring
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Postoperative cerebral oxygen saturation decreases
Number of subjects: 96
Study: 31862526

Group type: EXPERIMENTAL
Intervention: Sub-millimeter fMRI methodology
Number of subjects: 0
Study: 31863283

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg starting dose
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg starting dose in Del19-positive patients
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg starting dose in Asian patients
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Sequential afatinib and osimertinib
Number of subjects: 169
Study: 31863305

Group type: EXPERIMENTAL
Intervention: CYP2D6-specific drugs
Number of subjects: 287
Study: 31863744

Group type: EXPERIMENTAL
Intervention: Endovascular occlusion (EV)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Microsurgical exclusion (MS)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 310
Study: 31865308

Group type: EXPERIMENTAL
Intervention: Measured Resting Energy Expenditure (REE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone and interleukin-6 plasma levels
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: REE-to-lean body mass (LBM) ratio
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nutritional markers (transthyretin)
Number of subjects: 27
Study: 31865389

Group type: EXPERIMENTAL
Intervention: CRT with LVWT <6 mm (≤20% group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRT with LVWT 20-50%
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRT with LVWT ≥50%
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRT with LVWT ≥25%
Number of subjects: 54
Study: 31865391

Group type: EXPERIMENTAL
Intervention: Recent-onset paroxysmal or persistent AF
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Left atrial volume
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor-1 (PAI-1)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: AF progression
Number of subjects: 392
Study: 31865481

Group type: EXPERIMENTAL
Intervention: BOMET-QoL-10 questionnaire
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for pain
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Self-perceived health status item
Number of subjects: 172
Study: 31865734

Group type: EXPERIMENTAL
Intervention: Hydrogen-oxygen therapy for 0.5, 1, and 2 months
Number of subjects: 3
Study: 31865771

Group type: EXPERIMENTAL
Intervention: Patients with LVH and elevated cardiac biomarkers
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study: 31865797

Group type: EXPERIMENTAL
Intervention: Change in NT-proBNP level over 3.2 years
Number of subjects: 4563
Study: 31865965

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31866281

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg orally twice per day in 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 106
Study: 31866516

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg intrauterine system
Number of subjects: 1513
Study: 31866855

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17
Study: 31866924

Group type: EXPERIMENTAL
Intervention: Occupation-Based Telerehabilitation Intervention
Number of subjects: 0
Study: 31867125

Group type: EXPERIMENTAL
Intervention: Posterior-Anterior Mobilization (PAM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Anterior-Posterior Mobilization (APM)
Number of subjects: 12
Study: 31867430

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31867437

Group type: EXPERIMENTAL
Intervention: Admission to a cardiology department
Number of subjects: 3677

Group type: COMPARATOR
Intervention: Standard care (not involving a cardiology department)
Number of subjects: 3677
Study: 31867564

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimum clinically important difference (MCID) of 0.22
Number of subjects: 0
Study: 31868043

Group type: EXPERIMENTAL
Intervention: Asthma shared decision making (SDM) intervention
Number of subjects: 10
Study: 31868121

Group type: EXPERIMENTAL
Intervention: Predictive equations (PEq) for RMR estimation
Number of subjects: 56
Study: 31868997

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (58%)
Number of subjects: 2063

Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (32%)
Number of subjects: 2063

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L visual analogue score
Number of subjects: 2063

Group type: EXPERIMENTAL
Intervention: Co-morbidities
Number of subjects: 2063

Group type: EXPERIMENTAL
Intervention: ECOG performance score
Number of subjects: 2063
Study: 31869400

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Trastuzumab administration
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment (86% epirubicin, 7% doxorubicin)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 929
Study: 31869407

Group type: EXPERIMENTAL
Intervention: Arterial thrombosis after MPN diagnosis
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Arterial thrombosis
Number of subjects: 647
Study: 31869413

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with conditioning consisting of carmustine, etoposide, cytarabine, melphalan, and alemtuzumab.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with donor lymphocyte infusions (DLI) for mixed chimerism or residual or relapsed disease.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Number of subjects: 31